spacer
home > ict > autumn 2009 > asean all-stars
PUBLICATIONS
International Clinical Trials

ASEAN All-Stars

 

The clinical trial landscape has changed dramatically over the past decade. Whereas at the turn of the century, almost all clinical trial research was carried out in the US and western Europe, US-based drug sponsors indicate that up to 50 per cent of studies are now conducted outside of the US and expect that figure to increase to 65 per cent within three years (1). In 1990, clinical trials were conducted in about 28 countries worldwide. In September 2009, the FDA was regulating 78,276 trials in 172 countries, and the European Medicines Agency (EMEA) expects the trend to conduct more clinical trials in developing nations to increase in years to come.

There are a number of reasons for this shift. Lower costs, access to large numbers of treatment-naďve patients, the potential for fast patient recruitment and the opportunity to expand their presence in emerging markets are among the top reasons pharmaceutical companies are now conducting trials in developing nations. South-east Asia is an increasingly popular destination because it offers all of these benefits.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Muddyman is the Managing Director and CEO of Conversis, a leading provider of globalisation, internationalisation, localisation and translation services, specialising in the life sciences sector. Gary started Conversis back in 2003 with the intention of advancing the understanding and use of localisation and translation as a strategic business tool. Before that, he spent 16 years at HSBC.
spacer
Garry Muddyman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines

Ajdovšcina, Slovenia & Bangkok, Thailand, 02 November 2021: BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, today announced the successful development of an optimized mRNA manufacturing process.
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement